Molecular Partners : Annual General Meeting Minutes
Minutes of the 19th Annual General Meeting of the Shareholders of MOLECULAR PARTNERS AG, held at 9:00 a.m. on 17 April 2024 at JED Events, Zürcherstrasse 39,...
Source: marketscreener.com
Michael Vasconcelles News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Michael Vasconcelles. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Michael Vasconcelles Today - Breaking & Trending Today
FDA Prioritizes Review of Elahere in Ovarian Cancer
The Food and Drug Administration has set priority review for Elahrere as use of treatment in patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Source: curetoday.com
ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH
Pivekimab Triplet Demonstrates Encouraging CR, Composite CR, and MRD Negativity Rates; Broad Anti-Leukemia Activity Observed Across All Molecular Subsets Evaluated Pivekimab-Containing Triplet...
Source: marketscreener.com
FDA to Review Confirmatory Data for Elahere in Platinum-Resistant Ovarian Cancer
The FDA has accepted for Priority Review the sBLA supporting the conversion to full approval of Elahere for platinum-resistant ovarian cancer.
Source: endocrinologyadvisor.com
FDA Grants Priority Review to Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer
The FDA has granted priority review to the supplemental biologics license application seeking the conversion of the accelerated approval of mirvetuximab soravtansine-gynx in patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who previously received 1 to 3 lines of systemic treatment to full approval.
Source: onclive.com